A phase I, extended release formulations trial of ACH-4471 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2017
At a glance
- Drugs ACH 4471 (Primary)
- Indications Glomerulonephritis; Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Achillion Pharmaceuticals
- 07 Nov 2017 New trial record
- 02 Nov 2017 According to Achillion media release, company plans to initiate the trial by the end of 2017.